New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2013
09:47 EDTPFE, PLXProtalix rallies following report of takeover talks
Shares of Israeli pharmaceutical company Protalix (PLX) are soaring after Israeli website Calcalist reported that the company is in talks to be acquired for $1B. Pfizer has expressed interest in buying Protalix, but at a valuation below the amount that Protalix is seeking, the website added. Protalix's board has selected Citigroup (C) to manage the selling process, according to Calcalist. In early trading, Protalix jumped 94c, or 18%, to $6.34. Reference Link
News For PLX;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2015
05:40 EDTPLXProtalix assumed with a Buy from Hold at Jefferies
Jefferies upgraded Protalix to Buy after assuming coverage of the name and raised its price target for shares to $2.60 from $2.00. The firm says Protalix's pipeline is growing beyond Elelyso.
April 21, 2015
10:01 EDTPFEPfizer receives FDA breakthrough therapy designation for Xalkori
Subscribe for More Information
08:18 EDTPFEPain Therapeutics resumes responsibility for Remoxy
Subscribe for More Information
08:06 EDTPFEPfizer says Phase 3 inotuzumab ozogamicin study met first primary endpoint
Subscribe for More Information
April 20, 2015
16:40 EDTPLXCamber Capital reports 5.37% passive stake in Protalix
08:02 EDTPFEMerck KGaA, Pfizer initiate Phase III study with Avelumab
Subscribe for More Information
06:05 EDTPFEProvectus receives notice of allowance for PV-10 combined with other drugs
Subscribe for More Information
April 15, 2015
08:04 EDTPFEPfizer: PALOMA-3 trial for IBRANCE met primary endpoint, trial stopped early
Subscribe for More Information
April 13, 2015
15:12 EDTPFEMylan enters settlement, license agreement with Pfizer regarding Viagra
Mylan (MYL) announced that its subsidiaries Mylan Inc. and Mylan Pharmaceuticals have entered into a settlement and license agreement with Pfizer (PFE), Pfizer Limited and Pfizer Ireland Pharmaceuticals to settle patent litigation relating to Mylan's Abbreviated New Drug Application filed with the U.S. FDA for Sildenafil Citrate Tablets 25 mg, 50 mg, and 100 mg. This product is the generic version of Viagra, which is indicated to treat erectile dysfunction. Under the terms of the agreement, Mylan will be able to launch its ANDA products pursuant to a royalty-bearing license as early as December 11, 2017, or sooner under certain conditions, subject to FDA approval. All other terms and conditions of the settlement and license agreement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission. For the 12 months ending Dec. 31, 2014, Viagra had U.S. sales of approximately $1.3B, according to IMS Health.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use